We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection.
- Authors
Eun Jin Kim; Sun Ha Choi; Jae Seok Park; Yong Shik Kwon; Jaehee Lee; Yeonjae Kim; Shin Yup Lee; Eun Young Choi
- Abstract
We retrospectively reviewed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections who were admitted to an intensive care unit in Daegu, South Korea. The outcomes of patients who did (cases) or did not (controls) receive darunavir-cobicistat (800-150 mg) therapy were compared. Fourteen patients received darunavir-cobicistat treatment, and 96 received other antiviral therapy (controls). Overall, the darunavir-cobicistat group comprised patients with milder illness, and the crude mortality rate of all patients in the darunavir-cobicistat group was lower than that in the controls [odds ratio (OR) 0.20, 95% confidence interval (CI) 0.04-0.89, p=0.035]. After 1:2 propensity-score matching, there were 14 patients in the darunavir-cobicistat group, and 28 patients in the controls. In propensity score-matched analysis, the darunavir-cobicistat group had lower mortality than the controls (OR 0.07, 95% CI 0.01-0.52, p=0.009). In conclusion, darunavir-cobicistat therapy was found to be associated with a significant survival benefit in critically ill patients with SARS-CoV-2 infection.
- Subjects
TAEGU (Korea); SARS-CoV-2; CRITICALLY ill; COVID-19; INTENSIVE care units
- Publication
Yonsei Medical Journal, 2020, Vol 61, Issue 9, p826
- ISSN
0513-5796
- Publication type
Article
- DOI
10.3349/ymj.2020.61.9.826